How do you take a tiny private Swedish biotech and turn it into a successful, publicly-listed company operating on both sides of the Atlantic, in just six years? Listen to Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, tell Optimum’s Richard Staines how they brought TARPEYO, the first FDA-approved drug for the rare kidney disease primary IgA nephropathy, to market.She describes her ‘incredible journey’ growing the firm from less than 10 staff to more than 200, taking it public in Europe and the US, running a global Phase III trial, and how Tarpeyo can help people with IgA nephropathy live more normal lives.https://www.optimumcomms.com/podcastFollow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! Follow and Subscribe today. #optimumperspectivespodcast Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios